se of micafungin as antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Not Applicable
- Conditions
- hematological malignancies
- Registration Number
- JPRN-UMIN000001905
- Lead Sponsor
- The Jikei university school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are free of fungal infection at the time of enrollment. Patients have a history of a serious allergy to the study drug. Patients have a serious liver dysfunction. Patients have received micafungin within 7 days before the time of enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point is treatment success, which is defined as the absence of fungal infection through the prophylaxis therapy of micafungin and as the absence of fungal infection through the end of the 4-week posttreatment period.
- Secondary Outcome Measures
Name Time Method